OBJECTIVES: Very little information is available about treatment protocols for Crohn’s disease (CD) in Brazil. The objective of this study was to examine pharmacoepidemiological data to identify how CD has been treated in Brazil and consider the need for additional treatment options.  METHODS: Patients with CD and their treatments were analyzed retrospectively from the Brazilian Unified Health System (SUS) database, the DATASUS. The study period was defined as January 2008 to December 2014, with emphasis on the last two years. CD was identified by the International Code of Diseases (ICD) 10 code K50 in the prescription claims. The analyzed variables included age, gender, geographical region and therapy.  RESULTS: In DATASUS during 2013 (n=27,904) and 2014 (n=31,029), approximately 71% of patients with CD were age 25 to 60 years and 56% were female. In 2014, the majority of treated patients were located in the Southeast region (n=19,938, 64%), and the state with the highest number of treated patients was São Paulo (n=12,803 41%). Mesalazine and azathioprine were used in 69% of patients; adalimumab and infliximab were used in 26% of patients. The number of patients who were treated for CD increased 49% from 2008 to 2014 and use of biologic therapies increased 4.5 times. Biologics with the highest growth rates between 2013 and 2014 were adalimumab (30%) and infliximab (23%), indicating an increasing demand.  The prevalence of CD management (per 1000 people in the general population) varied in the different geographical regions:  Southeast (23), South (18), Northeast (6), Midwest (11) and North   (1). CONCLUSIONS: While the number of patients with CD who are treated with biologics is increasing overall, we observed a large discrepancy in the prevalence of therapy by geographical region. Recent increases in the use of biologics suggest a need for additional treatment options for CD in Brazil.